Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=166"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=166

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00121108-1a43adaf",
        "title": "Motavizumab vs Placebo: Number of Participants With RSV Outpatient Medically Attended Lower Respiratory Illness (MA LRI)",
        "summary": "41 of 1417 against 71 of 710; risk difference -7.1 points, 95% interval -9.6 to -4.9; NCT00121108, MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States",
        "record": "/library/comparisons/NCT00121108-1a43adaf",
        "nct_id": "NCT00121108",
        "kind": "outcome",
        "participants": 2127,
        "risk_difference": {
          "value": -0.07106563161609034,
          "lower": -0.0964735215881775,
          "upper": -0.04870402940926678
        },
        "group_1": "41 of 1,417",
        "group_2": "71 of 710",
        "difference": "-7.1 points",
        "interval": "-9.6 to -4.9",
        "trial_title": "MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States"
      },
      {
        "id": "NCT00121108-76411a78",
        "title": "Motavizumab vs Placebo: Number of Participants With Medically Attended-Otitis Media (MA-OM) Events",
        "summary": "532 of 1417 against 275 of 710; risk difference -1.2 points, 95% interval -5.6 to 3.2; NCT00121108, MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States",
        "record": "/library/comparisons/NCT00121108-76411a78",
        "nct_id": "NCT00121108",
        "kind": "outcome",
        "participants": 2127,
        "risk_difference": {
          "value": -0.011882870973192683,
          "lower": -0.05590941448863594,
          "upper": 0.03154028816849494
        },
        "group_1": "532 of 1,417",
        "group_2": "275 of 710",
        "difference": "-1.2 points",
        "interval": "-5.6 to 3.2",
        "trial_title": "MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=167",
  "request_id": "WxOlqYCCTRZ8c74j"
}